UK markets closed

Heron Therapeutics, Inc. (0J4V.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
3.1020+0.2650 (+9.34%)
At close: 03:44PM BST
Full screen
Previous close2.8370
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range3.1020 - 3.1020
52-week range3.1020 - 3.1020
Avg. volumeN/A
Market cap247.131M
Beta (5Y monthly)1.39
PE ratio (TTM)N/A
EPS (TTM)-2.2930
Earnings date08 Aug 2022 - 12 Aug 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates

    Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -40% and 6.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

  • Motley Fool

    Up 1,000% in 5 Years? These Healthcare Stocks Could Pull It Off.

    Patrick Bafuma is bullish on Legend Biotech (NASDAQ: LEGN) and thinks it might be worth $55 billion by 2027. George Budwell believes his pick, Heron Therapeutics (NASDAQ: HRTX), could jump 1,000% in that time frame. Patrick Bafuma (Legend Biotech): Lost amid the recent market doldrums has been some incredible news.

  • Motley Fool

    Why Heron Therapeutics Stock Is Getting Hammered Today

    Shares of the small-cap biotech Heron Therapeutics (NASDAQ: HRTX) are down by a noteworthy 19.2% as of 2:48 p.m. ET Tuesday afternoon. The lack of commercial momentum for Heron's non-opioid painkiller Zynrelef appears to be the biggest concern for shareholders today. Heron has been one of the most heavily shorted stocks on the Nasdaq stock exchange for quite a while now.